Skip to main content
$42.57 -$1.55 (-3.5%)

04:00 PM EDT on 06/05/23

PTC Therapeutics (NASDAQ:PTCT)

CAPS Rating: No stars

Current Price $42.57 Mkt Cap $3.2B
Open $43.83 P/E Ratio -5.39
Prev. Close $42.57 Div. (Yield) $0.00 (0.0%)
Daily Range $42.26 - $43.92 Volume 599,392
52-Wk Range $25.01 - $59.84 Avg. Daily Vol. 878,479


How do you think NASDAQ:PTCT will perform against the market?

Add Stock to CAPS Watchlist

All Players

22 Outperform
13 Underperform

All-Star Players

5 Outperform
6 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:PTCT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TSIF (99.99)
Submitted February 23, 2016

I'm not sure which is more mysterious...1. That the company hasn't chimed in yet with a plan of action well into the day it's stock cratered from an FDA "refuse to file" letter.2. That the company was inept enough to file an application that was so… More

noataluren (< 20)
Submitted May 28, 2014

As a former PTC employee, this recommendation for conditional approval is a joke. None of the data are strong. The improvement for the 40 mg/kg/day dose over placebo was significant (after eliminating 2 patients whose baseline data was faulty) in the… More

Recent Community Commentary

Read the most recent pitches from players about PTCT.


Member Avatar TMFBiologyFool (67.13) Submitted: 6/19/2018 5:31:18 PM : Outperform Start Price: $35.00 NASDAQ:PTCT Score: -32.97

Overreaction to SRPT gene therapy data.


Member Avatar MarkBiotech (< 20) Submitted: 3/7/2018 4:30:35 PM : Outperform Start Price: $27.90 NASDAQ:PTCT Score: -5.36

the quick uptake and strong launch of SRPT's Exondy's has shown us how large of a need their is for DMD patients. Despite the public backlash on emflaza's pricing, its launch still continues to be very strong.. Also ataluren's EU sales are progessing nicely.. the eventual approval(despite CRL) for ataluren in the US should give PTCT a good boost in future value.. Guidance for 2018 stands at 260-295M(VS 300M for srpt).. that puts PTCT valuation at 4x 2018 sales which is considered VERY CHEAP.. This valuation is also undermining RG7916 in SMA which has shown robust preliminary data. i could see PTCT double in the near future due to its low valuation.. PT- 60


Member Avatar zzlangerhans (99.38) Submitted: 5/26/2016 5:14:18 PM : Underperform Start Price: $7.88 NASDAQ:PTCT Score: -336.31

PTC continues to have its ups and downs since the February crash but I share the view of the FDA that there is no evidence Translarna is effective. I think there's a good chance that CHMP will revoke the conditional approval within the next few months, but the chance that they do not is enough to keep me from shorting the stock. CHMP seems to have a somewhat different mentality about placebos than the FDA. Regardless, one day the truth will finally be apparent to all and PTC will stop diverting valuable and limited resources away from treatments that might actually work.


Find the members with the highest scoring picks in PTCT.

Score Leader


stainsolution (< 20) Score: +530.38

The Score Leader is the player with the highest score across all their picks in PTCT.

Member Name Member
Call Time
Score Commentary
stainsolution < 20 3/1/2016 Outperform 5Y $5.70 +646.84% +116.46% +530.38 0 Comment
portefeuille 98.44 3/1/2016 5/31/2021 Outperform NS $6.42 +563.08% +117.95% +445.13 0 Comment
wkdkdka84 < 20 6/23/2016 Outperform 5Y $6.98 +510.32% +102.60% +407.72 0 Comment
saxjax 49.90 8/19/2016 Outperform 5Y $8.12 +424.26% +95.64% +328.62 0 Comment
WudoUknow 74.04 2/29/2016 Outperform 5Y $7.84 +442.71% +120.27% +322.44 0 Comment
Playa14 < 20 4/6/2017 5/18/2022 Outperform 5Y $9.69 +339.32% +81.79% +257.53 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. skyrocket29 67.35 3/9/2017 9/5/2017 Outperform 3M $10.32 +312.50% +80.44% +232.06 0 Comment
NajdorfSicilian 99.43 4/20/2017 Outperform 5Y $11.20 +280.09% +81.32% +198.77 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Prodders 26.97 2/2/2017 Outperform 5Y $13.10 +224.96% +87.84% +137.12 0 Comment
Tqluu 75.94 5/18/2015 Underperform 5Y $52.43 -18.81% +101.23% +120.04 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PTCT.